| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 105, 147-152, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
BP Bidstrup, SR Underwood, RN Sapsford and EM Streets
To determine the effect on aorta-coronary bypass grafts of high-dose
aprotinin, a drug known to be effective in reducing bleeding after all
forms of heart operations, a prospective double-blind study was performed.
Graft patency was assessed noninvasively 7 to 12 days (median 9 days)
postoperatively in 90 patients. In the aprotinin group, 38 of 43 patients
had all grafts patent compared with 43 of 47 in the placebo group. In each
group, respectively, 126 of 131 grafts versus 134 of 138 grafts were
patent. Neither difference was statistically significant (p > 0.05).
Blood loss and homologous blood use were significantly reduced in the
aprotinin-treated patients. In this study, high-dose aprotinin did not
result in early saphenous vein graft occlusion after aorta-coronary bypass
operations. This is further evidence that aprotinin reduces hemostatic
derangement during cardiopulmonary bypass without creating a
"prothrombotic" situation.
ARTICLES
Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency
Humana Hospital Wellington, London, England.
This article has been cited by other articles:
|
|
 |
|
  J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Veres, T. Radovits, H. Schultz, L.-n. Lin, J. Hutter, E. Weigang, Z. Szabolcs, and G. Szabo Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 340 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Mangano, Y. Miao, A. Vuylsteke, I. C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M. L. Fontes, Z. Hillel, E. Ott, et al. Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery JAMA, February 7, 2007; 297(5): 471 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ronald and J. Dunning Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery? Interactive CardioVascular and Thoracic Surgery, December 1, 2006; 5(6): 767 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Mangano, I. C. Tudor, C. Dietzel, and the Multicenter Study of Perioperative Ischemia Re The Risk Associated with Aprotinin in Cardiac Surgery N. Engl. J. Med., January 26, 2006; 354(4): 353 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials, June 1, 2005; 2(3): 218 - 232. [Abstract] [PDF]
|
|
|
|
 |
|
 D. K.H. Leong, V. Ashok, A. Nishkantha, Y. H. Shan, and E. K.W. Sim Transit-Time Flow Measurement is Essential in Coronary Artery Bypass Grafting Ann. Thorac. Surg., March 1, 2005; 79(3): 854 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kalkat, A. Levine, and J. Dunning Does use of aprotinin in coronary artery bypass graft surgery affect graft patency? Interactive CardioVascular and Thoracic Surgery, March 1, 2004; 3(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Groom, J. Tryzelaar, R. Forest, K. Niimi, G. Cecere, D. Donegan, S. Katz, P. Weldner, R. Quinn, J. Braxton, et al. Intra-operative quality assessment of coronary artery bypass grafts Perfusion, December 1, 2001; 16(6): 511 - 518. [Abstract] [PDF]
|
|
|
|
|
|
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Bidstrup, B. J. Hunt, S. Sheikh, R. N. Parratt, J. M. Bidstrup, and R. N. Sapsford Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting Ann. Thorac. Surg., February 1, 2000; 69(2): 541 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Rich The efficacy and safety of aprotinin use in cardiac surgery Ann. Thorac. Surg., November 1, 1998; 66(90050): S6 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Gott, W. A. Cooper, F. E. Schmidt Jr, W. M. Brown III, C. E. Wright, J. D. Merlino, J. D. Fortenberry, W. S. Clark, and R. A. Guyton Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies Ann. Thorac. Surg., September 1, 1998; 66(3): 747 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Bidstrup Coronary Artery Bypass Graft Patency Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 282 - 287. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Hayashida, T. Isomura, T. Sato, H. Maruyama, K. Kosuga, and S. Aoyagi EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 261 - 269. [Abstract] [Full Text]
|
|
|
|
|
|
R. G. H. Speekenbrink, C. R. H. Wildevuur, A. Sturk, and L. Eijsman LOW-DOSE AND HIGH-DOSE APROTININ IMPROVE HEMOSTASIS IN CORONARY OPERATIONS J. Thorac. Cardiovasc. Surg., August 1, 1996; 112(2): 523 - 530. [Abstract] [Full Text]
|
|
|
|
|
|
S. K. Ohri, R. Paratt, J. M. Becket, J. Brannan, B. J. Hunt, and K. M. Taylor Genetically Engineered Serine Protease Inhibitor for Hemostasis After Cardiac Operations Ann. Thorac. Surg., April 1, 1996; 61(4): 1223 - 1230. [Abstract] [Full Text]
|
|
|
|
|
|
P. Hornick and A. George Blood contact activation: pathophysiological effects and therapeutic approaches Perfusion, January 1, 1996; 11(1): 3 - 19. [PDF]
|
|
|
|
|
|
J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Pifarre State-of-the-Art Review: Optimal Anticoagulation in Cardiovascular Surgery Clinical and Applied Thrombosis/Hemostasis, June 1, 1995; 1(3): 173 - 178. [Abstract] [PDF]
|
|
|
|
|
|
J. H. Lemmer Jr, W. Stanford, S. L. Bonney, E. V. Chomka, R. B. Karp, G. W. Laub, J. A. Rumberger, and H. V. Schaff Aprotinin for Coronary Artery Bypass Grafting: Effect on Postoperative Renal Function Ann. Thorac. Surg., January 1, 1995; 59(1): 132 - 136. [Abstract] [Full Text]
|
|
|
|
|
|
B. Blauhut, W. Harringer, P. Bettelheim, J. E. Doran, P. Spath, and P. Lundsgaard-Hansen Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1083 - 1091. [Abstract] [Full Text]
|
|
|
|
|
|
P. O. Daily, J. A. Lamphere, W. P. Dembitsky, R. M. Adamson, and N. F. Dans Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass graftingA randomized, prospective, double-blind study J. Thorac. Cardiovasc. Surg., July 1, 1994; 108(1): 99 - 108. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Lemmer Jr., W. Stanford, S. L. Bonney, J. F. Breen, E. V. Chomka, W. J. Eldredge, W. W. Holt, R. B. Karp, G. W. Laub, M. J. Lipton, et al. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patencyA multicenter, randomized, double-blind, placebo-controlled study J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 543 - 553. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Murkin, J. Lux, N. A. Shannon, G. M. Guiraudon, A. H. Menkis, F. N. McKenzie, and R. J. Novick Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 554 - 561. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
